# Pathalys Pharma

> Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company in Raleigh, North Carolina, developing advanced therapeutics for late-stage chronic kidney disease. Its lead asset is upacicalcet, a novel non-peptide calcimimetic given intravenously at the end of a hemodialysis session for secondary hyperparathyroidism (SHPT) in patients with end-stage kidney disease.

This file was generated by [API Evangelist](https://apievangelist.com) on 2026-08-26 from the company's public website and the machine-readable surface it exposes. Pathalys Pharma does not publish an llms.txt of its own (https://pathalys.com/llms.txt returns 404), does not operate a developer program, and does not issue API credentials. Nothing here is a commitment by Pathalys.

## What Pathalys is

- Private, late-stage clinical biopharmaceutical company; headquarters at 4000 Center at North Hills Street, Suite 470, Raleigh, NC 27609.
- Created with initial funding from Catalys Pacific and the DaVita Venture Group as a multi-asset company focused on end-stage kidney disease.
- Lead asset: upacicalcet, a calcimimetic delivered by pre-filled syringe at the end of hemodialysis. An investigational product candidate in the United States, subject to FDA review and approval.
- January 2023: raised $150 million in secured product financing and equity led by Abingworth, with a development collaboration with Launch Therapeutics for the pivotal PATH Phase 3 program.
- August 2024: closed an oversubscribed $105 million Series B to fund NDA submission and pre-commercialization.

## Company pages

- [Home](https://pathalys.com/): company overview, the SHPT problem statement and the upacicalcet approach.
- [Team](https://pathalys.com/team/): leadership.
- [News](https://pathalys.com/news/): press releases and corporate announcements. RSS: https://pathalys.com/feed/
- [Scientific Updates](https://pathalys.com/scientific-updates/): published upacicalcet science.
- [Contact us](https://pathalys.com/contact/): corporate contact form.
- [Privacy Policy](https://pathalys.com/privacy-policy/)
- [Terms of Use](https://pathalys.com/terms-of-use/)

## Machine-readable surface

Pathalys ships no product API. The only machine-readable surface is the anonymously readable WordPress REST content API behind the corporate site.

- Base URL: https://pathalys.com/wp-json
- Namespace: wp/v2 (plus oembed/1.0)
- Authentication: none required for reads. No keys, no OAuth, no signup.
- Platform documentation: https://developer.wordpress.org/rest-api/

Read operations verified 200 anonymously on 2026-08-26:

- `GET /wp-json/wp/v2/posts` — 14 news items and scientific updates (2020-10-22 to 2026-05-22).
- `GET /wp-json/wp/v2/posts/{id}` — one item.
- `GET /wp-json/wp/v2/pages` — 7 corporate pages.
- `GET /wp-json/wp/v2/pages/{id}` — one page.
- `GET /wp-json/wp/v2/media` — 104 media items, including the Pathalys wordmark.
- `GET /wp-json/wp/v2/categories` — 2 terms: News (1), Scientific Updates (11).
- `GET /wp-json/wp/v2/search?search=...` — cross-content search over posts and pages.
- `GET /wp-json/` — site index: namespaces, full route table, site logo.
- `GET /wp-json/oembed/1.0/embed?url=...` — oEmbed 1.0 representation of any pathalys.com URL.

Conventions an agent needs:

- Pagination is `page` / `per_page` (max 100); read `X-WP-Total` and `X-WP-TotalPages`, and follow the RFC 8288 `Link` header.
- Trim payloads with `_fields=id,slug,title,link`; inline relationships with `_embed` instead of walking `_links`.
- Errors are the WordPress `WP_Error` envelope — `{"code","message","data":{"status"}}` — not RFC 9457 problem+json. Branch on `code`.
- No rate-limit headers are returned. robots.txt states `Crawl-delay: 10`; treat that as the pace. Responses are edge-cached for 600 seconds by WP Engine.
- The public surface is entirely read-only. There is no write, purchase, or dispatch operation, and therefore nothing to undo.

## What does not exist

Recorded so an agent stops looking rather than guessing:

- No OpenAPI or Swagger document published by Pathalys (`/openapi.json`, `/openapi.yaml`, `/swagger.json` all 404).
- No GraphQL endpoint (`/graphql` 404).
- No MCP server, remote or local. No published npm, PyPI, RubyGems or crates package. No GitHub organization.
- No A2A agent card at `/.well-known/agent-card.json` or `/.well-known/agent.json` (both 404).
- No `/.well-known/security.txt`, `openid-configuration`, `oauth-authorization-server`, `api-catalog`, or `ai-plugin.json` (all 404).
- No status page, SLA, changelog, deprecation policy, sandbox, CLI, SDK, or pricing page.

## API Evangelist artifacts in this profile

- openapi/ — seven derived OpenAPI 3.2.0 documents, one per content family.
- authentication/, conventions/, errors/, lifecycle/, conformance/, data-model/ — derived runtime semantics.
- rate-limits/, plans/ — measured zeros, with the evidence.
- well-known/, security/ — probe records.
- skills/ — packaged agent skills grounded in the real operationIds above.

## Corrections

This is an independent third-party profile. Corrections, re-scores and removal are free and require no justification: open an issue on https://github.com/api-evangelist/pathalys-pharma or email info@apievangelist.com.